INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
Please provide your email address to receive an email when new articles are posted on . Tyenne (tocilizumab-aazg) is available in a prefilled syringe, pen injector or vial. The biosimilar will launch ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
(RTTNews) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY), announced Monday that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application ...
AVTOZMA IV is approved for all same indications as the reference product Actemra ® (tocilizumab), including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic ...
We spotlight trailblazers in the entrepreneurship world, exploring their groundbreaking ventures, innovative strategies, and the latest trends shaping the business landscape. Fresh new ideas and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback